Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q6Y7W6
UPID:
GGYF2_HUMAN
Alternative names:
PERQ amino acid-rich with GYF domain-containing protein 2; Trinucleotide repeat-containing gene 15 protein
Alternative UPACC:
Q6Y7W6; A6H8W4; B9EG55; E9PBB0; O75137; Q7Z2Z8; Q7Z3I2; Q96HU4; Q9NV82
Background:
GRB10-interacting GYF protein 2 (GIGYF2) plays a pivotal role in cellular processes by acting as a key component of the 4EHP-GYF2 complex, which represses translation initiation. It bridges EIF4E2 to ZFP36/TTP, linking translation repression with mRNA decay, and is involved in regulating tyrosine kinase receptor signaling, including IGF1 and insulin receptors. Additionally, GIGYF2 assists in ribosome-associated quality control by sequestering mRNA caps, thus blocking ribosome initiation.
Therapeutic significance:
While the direct association of GIGYF2 with Parkinson disease 11 remains uncertain, understanding its complex role in cellular signaling and protein synthesis regulation could unveil novel therapeutic strategies, particularly in neurodegenerative disorders.